Assessment of autonomic dysfunction with the COMPASS-31 and its relationship with disease activity and cardiovascular risks in patients with psoriatic arthritis
- 21 March 2022
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 42 (9) , 1539-1548
Abstract
This study aimed to evaluate the autonomic dysfunction as assessed by the Composite Autonomic Symptom Score-31 (COMPASS-31) as well as its relationship with disease activity and cardiovascular risks in patients with psoriatic arthritis (PsA). This cross-sectional observational study involved 118 PsA patients (85 females, mean age 45.6 years) and 64 healthy subjects. Cardiovascular risks were recorded including body mass index (BMI), hypertension (HT), diabetes mellitus (DM), dyslipidemia, metabolic syndrome (MetS), and 10-year Framingham Risk scores (FRS) were calculated. PsA was assessed with regard to disease activity, quality of life, and function. Autonomic dysfunction was evaluated using the COMPASS-31 consisting of six subdivisions including orthostatic, vasomotor, secretomotor, gastrointestinal, bladder, and pupillomotor functions. The mean disease duration was 63.3 months. The mean total COMPASS-31 score was significantly higher in PsA patients than in controls (24.4 vs 11.1; p < 0.001), as were all sub-domain scores. COMPASS-31 scores were significantly lower in patients with DAPSA-REM and MDA. The COMPASS-31 total score showed significant correlations with scores of pain, global assessment, fatigue, function, quality of life, DAPSA, and BASDAI (p < 0.05).The presence of HT, dyslipidemia, MetS, and abdominal obesity did not significantly affect the total COMPASS-31 and sub-domain scores, except for the secretomotor scores being significantly higher in patients with abdominal obesity and MetS (p < 0.05). COMPASS-31 scores were not significantly different across the FRS risk groups. The symptoms of autonomic dysfunction are prevalent in PsA patients. High disease activity and pain have negative effects on autonomic function, and also functional impairment, fatigue, and poor quality of life are associated with autonomic dysfunction. However, the COMPASS-31 was found to be insufficient to demonstrate a clear relationship between autonomic dysfunction and cardiovascular risk.Keywords
This publication has 43 references indexed in Scilit:
- Association of cardiovascular risk using non-linear heart rate variability measures with the framingham risk score in a rural populationFrontiers in Physiology, 2013
- COMPASS 31: A Refined and Abbreviated Composite Autonomic Symptom ScoreMayo Clinic Proceedings, 2012
- Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatmentAnnals of the Rheumatic Diseases, 2010
- Cardiac autonomic dysfunction in patients with systemic lupus, rheumatoid arthritis and sudden death riskSrpski arhiv za celokupno lekarstvo, 2010
- Endotoxin depresses heart rate variability in mice: cytokine and steroid effectsAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2009
- Mild autonomic dysfunction in primary Sjögren's syndrome: a controlled studyArthritis Research & Therapy, 2008
- Diagnosis and Management of the Metabolic SyndromeCirculation, 2005
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983
- Measurement of patient outcome in arthritisArthritis & Rheumatism, 1980